Literature DB >> 20683768

Relation of melatonin to sleep architecture in children with autism.

Roberta M Leu1, Liya Beyderman, Emmanuel J Botzolakis, Kyla Surdyka, Lily Wang, Beth A Malow.   

Abstract

Children with autism often suffer from sleep disturbances, and compared to age-matched controls, have decreased melatonin levels, as indicated by urine levels of the primary melatonin metabolite, 6-sulfatoxymelatonin (6-SM). We therefore investigated the relationship between 6-SM levels and sleep architecture in children with autism spectrum disorders (ASD). Twenty-three children, aged 4-10 years, completed two nights of polysomnography and one overnight urine collection for measurement of urinary 6-SM excretion rate. Parents completed the Children's Sleep Habits Questionnaire. We found that higher urinary 6-SM excretion rates were associated with increased N3 sleep, decreased N2 sleep, and decreased daytime sleepiness. The results warrant further examination to examine the effects of supplemental melatonin on sleep architecture and daytime sleepiness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20683768      PMCID: PMC3746009          DOI: 10.1007/s10803-010-1072-1

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  40 in total

1.  Sleep problems in autism: prevalence, cause, and intervention.

Authors:  A L Richdale
Journal:  Dev Med Child Neurol       Date:  1999-01       Impact factor: 5.449

2.  Characterizing sleep in children with autism spectrum disorders: a multidimensional approach.

Authors:  Beth A Malow; Mary L Marzec; Susan G McGrew; Lily Wang; Lynnette M Henderson; Wendy L Stone
Journal:  Sleep       Date:  2006-12       Impact factor: 5.849

3.  Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism.

Authors:  I Nir; D Meir; N Zilber; H Knobler; J Hadjez; Y Lerner
Journal:  J Autism Dev Disord       Date:  1995-12

4.  Melatonin production in healthy infants: evidence for seasonal variations.

Authors:  Y Sivan; M Laudon; R Tauman; N Zisapel
Journal:  Pediatr Res       Date:  2001-01       Impact factor: 3.756

5.  The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children.

Authors:  J A Owens; A Spirito; M McGuinn
Journal:  Sleep       Date:  2000-12-15       Impact factor: 5.849

6.  Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders: prevalence, severity, and pattern.

Authors:  Jennifer L Couturier; Kathy N Speechley; Margaret Steele; Ross Norman; Bernadette Stringer; Rob Nicolson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-08       Impact factor: 8.829

7.  The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.

Authors:  Juthamas Wirojanan; Sebastien Jacquemont; Rafael Diaz; Susan Bacalman; Thomas F Anders; Randi J Hagerman; Beth L Goodlin-Jones
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

8.  Basic aspects of melatonin action.

Authors:  D P Cardinali; P Pévet
Journal:  Sleep Med Rev       Date:  1998-08       Impact factor: 11.609

9.  Sleep patterns of children with pervasive developmental disorders.

Authors:  Ryan D Honomichl; Beth L Goodlin-Jones; Melissa Burnham; Erika Gaylor; Thomas F Anders
Journal:  J Autism Dev Disord       Date:  2002-12

10.  Sleep patterns and sleep disorders in children with autistic spectrum disorders: insights using parent report and actigraphy.

Authors:  Luci Wiggs; Gregory Stores
Journal:  Dev Med Child Neurol       Date:  2004-06       Impact factor: 5.449

View more
  21 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

2.  Assessing the Dim Light Melatonin Onset in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability.

Authors:  Emma K Baker; Amanda L Richdale; Agnes Hazi; Luke A Prendergast
Journal:  J Autism Dev Disord       Date:  2017-07

3.  Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep.

Authors:  Suzanne E Goldman; Karen W Adkins; M Wade Calcutt; Melissa D Carter; Robert L Goodpaster; Lily Wang; Yaping Shi; Helen J Burgess; David L Hachey; Beth A Malow
Journal:  J Autism Dev Disord       Date:  2014-10

4.  In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism.

Authors:  Danielle M Cusmano; Jessica A Mong
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

5.  Quantitation of melatonin and n-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS.

Authors:  Melissa D Carter; M Wade Calcutt; Beth A Malow; Kristie L Rose; David L Hachey
Journal:  J Mass Spectrom       Date:  2012-03       Impact factor: 1.982

Review 6.  The medical care of children with autism.

Authors:  Hilde Olivié
Journal:  Eur J Pediatr       Date:  2012-01-18       Impact factor: 3.183

7.  Comparison of melatonin with growth factors in promoting precursor cells proliferation in adult mouse subventricular zone.

Authors:  Areechun Sotthibundhu; Kasima Ekthuwapranee; Piyarat Govitrapong
Journal:  EXCLI J       Date:  2016-12-21       Impact factor: 4.068

8.  A Review of Sleep Disturbances among Infants and Children with Neurodevelopmental Disorders.

Authors:  Dana Kamara; Theodore P Beauchaine
Journal:  Rev J Autism Dev Disord       Date:  2019-12-26

Review 9.  Melatonin in children with autistic spectrum disorders: recent and practical data.

Authors:  C Doyen; D Mighiu; K Kaye; C Colineaux; C Beaumanoir; Y Mouraeff; C Rieu; P Paubel; Y Contejean
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-02-26       Impact factor: 4.785

Review 10.  The neurology of autism spectrum disorders.

Authors:  Shafali S Jeste
Journal:  Curr Opin Neurol       Date:  2011-04       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.